Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216

B. Mohelnikova-Duchonova, M. Kocik, B. Duchonova, V. Brynychova, M. Oliverius, J. Hlavsa, E. Honsova, J. Mazanec, Z. Kala, I. Ojima, DJ. Hughes, JE. Doherty, HA. Murray, MA. Crockard, R. Lemstrova, P. Soucek,

. 2017 ; 17 (5) : 452-460. [pub] 20160830

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18025319

Grantová podpora
NV16-28375A MZ0 CEP - Centrální evidence projektů

Digitální knihovna NLK
Plný text - Článek

E-zdroje Online Plný text

NLK ProQuest Central od 2001-01-01 do Před 1 rokem
Open Access Digital Library od 2001-01-01
Health & Medicine (ProQuest) od 2001-01-01 do Před 1 rokem

Odkazy

PubMed 27573236
DOI 10.1038/tpj.2016.55
Knihovny.cz E-zdroje

The Hedgehog pathway is one of the major driver pathways in pancreatic ductal adenocarcinoma. This study investigated prognostic importance of Hedgehog signaling pathway in pancreatic cancer patients who underwent a radical resection. Tumors and adjacent non-neoplastic pancreatic tissues were obtained from 45 patients with histologically verified pancreatic cancer. The effect of experimental taxane chemotherapy on the expression of Hedgehog pathway was evaluated in vivo using a mouse xenograft model prepared using pancreatic cancer cell line Paca-44. Mice were treated by experimental Stony Brook Taxane SB-T-1216. The transcript profile of 34 Hedgehog pathway genes in patients and xenografts was assessed using quantitative PCR. The Hedgehog pathway was strongly overexpressed in pancreatic tumors and upregulation of SHH, IHH, HHAT and PTCH1 was associated with a trend toward decreased patient survival. No association of Hedgehog pathway expression with KRAS mutation status was found in tumors. Sonic hedgehog ligand was overexpressed, but all other downstream genes were downregulated by SB-T-1216 treatment in vivo. Suppression of HH pathway expression in vivo by taxane-based chemotherapy suggests a new mechanism of action for treatment of this aggressive tumor.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18025319
003      
CZ-PrNML
005      
20241008084501.0
007      
ta
008      
180709s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/tpj.2016.55 $2 doi
035    __
$a (PubMed)27573236
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Mohelnikova-Duchonova, B $u Department of Toxicogenomics, National Institute of Public Health, Prague, Czech Republic. Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic.
245    10
$a Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216 / $c B. Mohelnikova-Duchonova, M. Kocik, B. Duchonova, V. Brynychova, M. Oliverius, J. Hlavsa, E. Honsova, J. Mazanec, Z. Kala, I. Ojima, DJ. Hughes, JE. Doherty, HA. Murray, MA. Crockard, R. Lemstrova, P. Soucek,
520    9_
$a The Hedgehog pathway is one of the major driver pathways in pancreatic ductal adenocarcinoma. This study investigated prognostic importance of Hedgehog signaling pathway in pancreatic cancer patients who underwent a radical resection. Tumors and adjacent non-neoplastic pancreatic tissues were obtained from 45 patients with histologically verified pancreatic cancer. The effect of experimental taxane chemotherapy on the expression of Hedgehog pathway was evaluated in vivo using a mouse xenograft model prepared using pancreatic cancer cell line Paca-44. Mice were treated by experimental Stony Brook Taxane SB-T-1216. The transcript profile of 34 Hedgehog pathway genes in patients and xenografts was assessed using quantitative PCR. The Hedgehog pathway was strongly overexpressed in pancreatic tumors and upregulation of SHH, IHH, HHAT and PTCH1 was associated with a trend toward decreased patient survival. No association of Hedgehog pathway expression with KRAS mutation status was found in tumors. Sonic hedgehog ligand was overexpressed, but all other downstream genes were downregulated by SB-T-1216 treatment in vivo. Suppression of HH pathway expression in vivo by taxane-based chemotherapy suggests a new mechanism of action for treatment of this aggressive tumor.
650    _2
$a senioři $7 D000368
650    _2
$a zvířata $7 D000818
650    _2
$a duktální karcinom slinivky břišní $x farmakoterapie $x genetika $7 D021441
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a proteiny hedgehog $x genetika $7 D053823
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši nahé $7 D008819
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mutace $7 D009154
650    _2
$a nádory slinivky břišní $x farmakoterapie $x genetika $7 D010190
650    _2
$a protoonkogenní proteiny p21(ras) $x genetika $7 D016283
650    _2
$a taxoidy $x aplikace a dávkování $x terapeutické užití $7 D043823
650    _2
$a transkriptom $x účinky léků $7 D059467
650    _2
$a výsledek terapie $7 D016896
650    _2
$a xenogenní modely - testy protinádorové aktivity $7 D023041
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kocik, M $u Department of Transplantation Surgery, Institute of Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Duchonova, B $u Palacky University, Olomouc, Czech Republic.
700    1_
$a Brynychová, Veronika $u Department of Toxicogenomics, National Institute of Public Health, Prague, Czech Republic. Charles University in Prague, Prague, Czech Republic. $7 xx0323150
700    1_
$a Oliverius, M $u Department of Transplantation Surgery, Institute of Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Hlavsa, J $u Department of Surgery, University Hospital and Medical Faculty, Masaryk University, Brno, Czech Republic.
700    1_
$a Honsova, E $u Department of Clinical and Transplantation Pathology, Institute of Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Mazanec, J $u Department of Pathology, University Hospital and Medical Faculty, Masaryk University, Brno, Czech Republic.
700    1_
$a Kala, Z $u Department of Surgery, University Hospital and Medical Faculty, Masaryk University, Brno, Czech Republic.
700    1_
$a Ojima, I $u Institute of Chemical Biology and Drug Discovery, State University of New York at Stony Brook, Stony Brook, NY, USA.
700    1_
$a Hughes, D J $u Department of Physiology &Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin 2, Ireland.
700    1_
$a Doherty, J E $u Randox Laboratories, Crumlin, UK.
700    1_
$a Murray, H A $u Randox Laboratories, Crumlin, UK.
700    1_
$a Crockard, M A $u Randox Laboratories, Crumlin, UK.
700    1_
$a Lemstrova, R $u Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic.
700    1_
$a Soucek, P $u Department of Toxicogenomics, National Institute of Public Health, Prague, Czech Republic.
773    0_
$w MED00008068 $t Pharmacogenomics journal $x 1473-1150 $g Roč. 17, č. 5 (2017), s. 452-460
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27573236 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20241008084458 $b ABA008
999    __
$a ok $b bmc $g 1317450 $s 1022240
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 17 $c 5 $d 452-460 $e 20160830 $i 1473-1150 $m Pharmacogenomics journal $n Pharmacogenomics J $x MED00008068
GRA    __
$a NV16-28375A $p MZ0
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace